Ms Danielle Lang
Research Academic
School of Medicine and Public Health
- Email:danielle.lang@newcastle.edu.au
- Phone:(02) 4014 3002
Career Summary
Biography
An experienced health economist with over 20 years’ experience, Danielle leads the Newcastle Evaluation Group (NEG), a multidisciplinary team renowned for their expertise in health technology assessment (HTA).
Founded in 1995, NEG is Australia's longest-standing university-based research group, contracted to provide evaluations of medicines for the Pharmaceutical Benefits Advisory Committee (PBAC), an independent expert body that recommends new medicines for listing on the Pharmaceutical Benefits Scheme (PBS).
NEG’s team brings diverse expertise in critical appraisal, medicine, pharmacy, biotechnology, health economics, and health policy, allowing them to comprehensively evaluate the clinical benefit, safety, cost-effectiveness, and financial impact of healthcare interventions.
While their work for the PBAC is confidential, the executive summaries of their reports form the basis of Public Summary Documents, which publicly outline crucial discussions regarding new medicine listings on the PBS.
NEG's work directly influences access to health technologies in Australia, especially through the PBS, which currently subsidises nearly 1,000 medicines, significantly improving the lives of Australians and costing over $15 billion annually.
Beyond the PBS, NEG has provided evaluations for the Medicare Services Advisory Committee (MSAC), the Australian Technical Advisory Group on Immunisation (ATAGI), the National Diabetes Services Scheme (NDSS), and the Agency for Care Effectiveness (ACE) in Singapore; and has conducted Post-Market Reviews of PBS-subsidised medicines, ensuring continued effectiveness and value.
Danielle has contributed to more than 200 confidential HTA reports across various domains such as cardiovascular disease, diabetes, and mental health, encompassing pharmaceuticals, vaccines, medical devices, and diagnostics, and has had reports of her scholarly work published in journals such as the Lancet and PLOS Medicine.
Since 1998, Danielle has attracted over $28 million in research funding, primarily from the Australian Department of Health and Aged Care.
Danielle has taught post-graduate health economics and economic evaluation and has developed teaching materials and conducted HTA workshops for the World Health Organization and the Singapore Ministry of Health, directly impacting healthcare decision-making on a global level.
Qualifications
- Post Graduate Diploma in Health Economics and Eval, Monash University
- Bachelor of Mathematics/Bachelor of Economics, University of Newcastle
Keywords
- economic evaluation
- economic modelling
- health economics
- pharmacoeconomics
Fields of Research
| Code | Description | Percentage |
|---|---|---|
| 380108 | Health economics | 100 |
Professional Experience
UON Appointment
| Title | Organisation / Department |
|---|---|
| Research Academic | University of Newcastle School of Medicine and Public Health Australia |
Teaching
| Code | Course | Role | Duration |
|---|---|---|---|
| PUBH6250 |
Health Economics The University of Newcastle |
Course Coordinator | 1/1/2004 - 19/9/2015 |
| PUBH6260 |
Clinical Economics The University of Newcastle |
Course coordinator | 1/7/2003 - 19/9/2015 |
| PUBH6290 |
Economic evaluation of health care University of Newcastle (previously PUBH6260 Clinical Economics) |
Course Coordinator | 1/7/2015 - 19/9/2015 |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (13 outputs)
| Year | Citation | Altmetrics | Link | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 |
Hinwood M, Wall L, Lang D, Balogh ZJ, Smith A, Dowsey M, et al., 'Patient and clinician characteristics and preferences for increasing participation in placebo surgery trials: a scoping review of attributes to inform a discrete choice experiment', TRIALS, 23 (2022) [C1]
|
Nova | |||||||||
| 2022 |
Wales K, Lang D, Rahja M, Somerville L, Laver K, Lannin NA, 'Economic Effects of Occupational Therapy Services for Adults in Acute and Subacute Care Settings: A Systematic Review.', Am J Occup Ther, 76 (2022) [C1]
|
Nova | |||||||||
| 2021 |
Lees S, Dicker M, Ku JE, Chaganti V, Mew-Sum M, Wang N, et al., 'Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis', BMJ OPEN, 11 (2021)
|
||||||||||
| 2015 |
Lang DL, Zhao FL, Robertson J, 'Prevention of postpartum haemorrhage: Cost consequences analysis of misoprostol in low-resource settings', BMC Pregnancy and Childbirth, (2015) [C1] © 2015 Lang et al. Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has been included in the World Health Organization... [more] © 2015 Lang et al. Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has been included in the World Health Organization Model List of Essential Medicines for use in the prevention of postpartum haemorrhage (PPH) in low-resource settings. This study evaluates the costs and health outcomes of use of oral misoprostol to prevent PPH in settings where injectable uterotonics are not available. Methods: A cost-consequences analysis was conducted from the international health system perspective, using data from a recent Cochrane systematic review and WHO's Mother-Baby Package Costing Spreadsheet in a hypothetical cohort of 1000 births in a mixed hospital (40 % births)/community setting (60 % births). Costs were estimated based on 2012 US dollars. Results: Using oxytocin in the hospital setting and misoprostol in the community setting in a cohort of 1000 births, instead of oxytocin (hospital setting) and no treatment (community setting), 22 cases of PPH could be prevented. Six fewer women would require additional uterotonics and four fewer women a blood transfusion. An additional 130 women would experience shivering and an extra 42 women fever. Oxytocin/misoprostol was found to be cost saving (US$320) compared to oxytocin/no treatment. Conclusions: Our findings confirm that, even though misoprostol is not the optimum choice in the prevention of PPH, misoprostol could be an effective and cost-saving choice where oxytocin is not or cannot be used due to a lack of skilled birth attendants, inadequate transport and storage facilities or where a quality assured oxytocin product is not available. These benefits need to be weighed against the large number of additional side effects such as shivering and fever, which have been described as tolerable and of short duration.
|
Nova | |||||||||
| 2007 |
Salkeld G, Henry DA, Hill SR, Lang DL, Freemantle N, D'Assuncao J, 'What drives health-care spending priorities? An international survey of health-care professionals', Plos Medicine, 4 256-259 (2007) [C1]
|
Nova | |||||||||
| 2003 |
Henry DA, Lang DL, 'Published pharmacoeconomic analyses: science or marketing?', Internal Medicine Journal, 33 404-404 (2003) [C3]
|
||||||||||
| 2003 |
Lopert R, Lang DL, Hill SR, 'Use of pharmacoeconomics in prescribing research. Part 3: cost-effectiveness analysis - a technique for decision-making at the margin', Journal of Clinical Pharmacy and Therapeutics, 28 243-249 (2003) [C1]
|
||||||||||
| 2003 |
Robertson J, Lang DL, Hill SR, 'Use of pharmacoeconomics in prescribing research. Part 1: costs - moving beyond the acquisition price for drugs', Journal of Clinical Pharmacy and Therapeutics, 28 73-79 (2003) [C1]
|
||||||||||
| 2002 |
Lopert R, Lang DL, Hill SR, Henry DA, 'Differential pricing of drugs: a role for cost-effectiveness analysis?', The Lancet, 359 2105-2107 (2002) [C1]
|
||||||||||
| 1999 |
Whitworth J, Lang DL, Henry DA, 'Cost-effectiveness Analysis in the Treatment of Hypertension: A Medical View', Clinical and Experimental Hypertension, 21(5-6) 999-1008 (1999) [C1]
|
||||||||||
| Show 10 more journal articles | |||||||||||
Conference (3 outputs)
| Year | Citation | Altmetrics | Link | |||||
|---|---|---|---|---|---|---|---|---|
| 2018 |
Wubishet B, Harris M, Lang D, Acharya S, Byles J, 'Rising diabetes prevalence among older Australian women', Melbourne, Australia (2018)
|
|||||||
| 2017 |
Wubishet B, Harris M, Abbas S, Lang D, acharya S, Byles J, 'Costs of major complications of Type 2 diabetes: A systematic review', Perth, Australia (2017)
|
|||||||
| 2017 |
Wubishet BL, Harris M, Abbas SS, Lang D, Acharya S, Byles J, 'COSTS OF MAJOR COMPLICATIONS OF TYPE 2 DIABETES: A SYSTEMATIC REVIEW', VALUE IN HEALTH (2017)
|
|||||||
Report (1 outputs)
| Year | Citation | Altmetrics | Link | ||
|---|---|---|---|---|---|
| 2001 |
Lowe J, Bonevski B, Carless P, Lopert R, Lang D, Deveridge S, et al., 'Universal Leucodepletion of Fresh Blood Products. A report comprising systematic review, stakeholder interviews and economic analysis', Commonwealth Department of Health and Aged Care (2001)
|
Grants and Funding
Summary
| Number of grants | 12 |
|---|---|
| Total funding | $28,180,101 |
Click on a grant title below to expand the full details for that specific grant.
20231 grants / $92,165
Analysing the economic and financial implications associated with expanding MBS items 12320 and 12322 for BMD testing to include patients aged 60-69 years$92,165
Funding body: Department of Health and Aged Care
| Funding body | Department of Health and Aged Care |
|---|---|
| Project Team | Ms Danielle Lang, Mr Rob Bell, Mr Jarrod Bell, Mr Marc Bevan, Ms Lynn Goon, Doctor Madeleine Hinwood, Doctor Emily Walkom |
| Scheme | Health Technology Assessment Services |
| Role | Lead |
| Funding Start | 2023 |
| Funding Finish | 2023 |
| GNo | G2300716 |
| Type Of Funding | C2100 - Aust Commonwealth – Own Purpose |
| Category | 2100 |
| UON | Y |
20211 grants / $5,985,069
The Provision Of External Evaluation Of Pharmaceutical Benefit Advisory Committee (PBAC) And Health Technology Related Submissions$5,985,069
Funding body: Department of Health and Aged Care
| Funding body | Department of Health and Aged Care |
|---|---|
| Project Team | Ms Danielle Lang, Mr Rob Bell, Mr Marc Bevan, Ms Lynn Goon, Doctor Madeleine Hinwood, Mr Jarrod Bell, Doctor Emily Walkom |
| Scheme | Pharmaceutical Benefits Advisory Committee (PBAC) and Health Technology Related Tender |
| Role | Lead |
| Funding Start | 2021 |
| Funding Finish | 2024 |
| GNo | G2100181 |
| Type Of Funding | C2100 - Aust Commonwealth – Own Purpose |
| Category | 2100 |
| UON | Y |
20201 grants / $178,382
Health Technology Assessment, Research Support and Other Services Panel$178,382
Funding body: Department of Health and Aged Care
| Funding body | Department of Health and Aged Care |
|---|---|
| Project Team | Ms Danielle Lang, Mr Rob Bell, Mr Marc Bevan, Doctor Emily Walkom, Mr Jarrod Bell, Ms Lynn Goon, Doctor Madeleine Hinwood |
| Scheme | Project Grant |
| Role | Lead |
| Funding Start | 2020 |
| Funding Finish | 2020 |
| GNo | G2000297 |
| Type Of Funding | C2100 - Aust Commonwealth – Own Purpose |
| Category | 2100 |
| UON | Y |
20181 grants / $18,667
Health Care Utilisation and Health Economics of Diabetes among Australian Women$18,667
Funding body: CEPAR (ARC Centre of Excellence in Population and Aging Health)
| Funding body | CEPAR (ARC Centre of Excellence in Population and Aging Health) |
|---|---|
| Project Team | Emeritus Professor Julie Byles, Doctor Melissa Harris, Ms Danielle Lang, Doctor Sham Acharya |
| Scheme | Research Supplementary Scholarship |
| Role | Investigator |
| Funding Start | 2018 |
| Funding Finish | 2020 |
| GNo | G1800586 |
| Type Of Funding | C2200 - Aust Commonwealth – Other |
| Category | 2200 |
| UON | Y |
20161 grants / $8,204,899
Provision of external evaluation of Pharmaceutical Benefits Advisory Committee (PBAC) and health technology related submissions$8,204,899
Funding body: Department of Health and Aged Care
| Funding body | Department of Health and Aged Care |
|---|---|
| Project Team | Ms Danielle Lang, Mr Jarrod Bell, Mr Rob Bell, Mr Marc Bevan, Ms Lynn Goon, Doctor Madeleine Hinwood, Doctor Emily Walkom, Miss Chiara Berardi |
| Scheme | Consultancy/Tender |
| Role | Lead |
| Funding Start | 2016 |
| Funding Finish | 2021 |
| GNo | G1601071 |
| Type Of Funding | C2100 - Aust Commonwealth – Own Purpose |
| Category | 2100 |
| UON | Y |
20141 grants / $53,923
Quotation for the provision of an evaluation of PBS Authority Required medicines using the Deed of Standing Offer SON 1503111 for the supply of PBS Medicines Review services$53,923
Funding body: Department of Health and Aged Care
| Funding body | Department of Health and Aged Care |
|---|---|
| Project Team | Mr Rob Bell, Ms Danielle Lang, Mr Marc Bevan |
| Scheme | Consultancy/Tender |
| Role | Investigator |
| Funding Start | 2014 |
| Funding Finish | 2014 |
| GNo | G1400929 |
| Type Of Funding | Other Public Sector - Commonwealth |
| Category | 2OPC |
| UON | Y |
20131 grants / $20,800
DoH Tender - Pharmaceutical Benefits Scheme (PBS) Medicines Review Panel$20,800
Funding body: Department of Health and Aged Care
| Funding body | Department of Health and Aged Care |
|---|---|
| Project Team | Mr Marc Bevan, Mr Rob Bell, Ms Danielle Lang |
| Scheme | Consultancy/Tender |
| Role | Investigator |
| Funding Start | 2013 |
| Funding Finish | 2013 |
| GNo | G1300519 |
| Type Of Funding | Other Public Sector - Commonwealth |
| Category | 2OPC |
| UON | Y |
20121 grants / $5,826,326
External Evaluation of PBAC Submissions RFT 086/1112 $5,826,326
Funding body: Department of Health and Aged Care
| Funding body | Department of Health and Aged Care |
|---|---|
| Project Team | Ms Danielle Lang, Doctor Barrie Stokes, Mr Marc Bevan, Mr Rob Bell, Doctor Fei-Li Zhao |
| Scheme | Consultancy/Tender |
| Role | Lead |
| Funding Start | 2012 |
| Funding Finish | 2016 |
| GNo | G1101212 |
| Type Of Funding | Other Public Sector - Commonwealth |
| Category | 2OPC |
| UON | Y |
20091 grants / $4,534,474
External Evaluation of PBAC Submissions RFT 360/0708$4,534,474
Funding body: Department of Health and Aged Care
| Funding body | Department of Health and Aged Care |
|---|---|
| Project Team | Doctor Jane Robertson, Ms Danielle Lang, Mr Rob Bell, Mr Marc Bevan |
| Scheme | Consultancy/Tender |
| Role | Investigator |
| Funding Start | 2009 |
| Funding Finish | 2012 |
| GNo | G0189557 |
| Type Of Funding | Other Public Sector - Commonwealth |
| Category | 2OPC |
| UON | Y |
20051 grants / $3,221,378
External Evaluation of PBAC Submissions RFP 163/0304$3,221,378
Funding body: Commonwealth Department of Health & Aged Care
| Funding body | Commonwealth Department of Health & Aged Care |
|---|---|
| Project Team | Ms Danielle Lang, Doctor Barrie Stokes, Doctor Jane Robertson |
| Scheme | Consultancy/Tender |
| Role | Lead |
| Funding Start | 2005 |
| Funding Finish | 2008 |
| GNo | G0184477 |
| Type Of Funding | Other Public Sector - Commonwealth |
| Category | 2OPC |
| UON | Y |
20041 grants / $1,066
2nd International Conference on Improving Use of Medicines (ICIUM2004), 30 March - 2 April 2004, Thailand$1,066
Funding body: University of Newcastle
| Funding body | University of Newcastle |
|---|---|
| Project Team | Ms Danielle Lang |
| Scheme | Travel Grant |
| Role | Lead |
| Funding Start | 2004 |
| Funding Finish | 2004 |
| GNo | G0183884 |
| Type Of Funding | Internal |
| Category | INTE |
| UON | Y |
20001 grants / $42,952
Local evaluation of the after hours primary medical care trial at Maitland Hospital.$42,952
Funding body: Hunter Urban Division of General Practice
| Funding body | Hunter Urban Division of General Practice |
|---|---|
| Project Team | Conjoint Professor Dianne O'Connell, Ms Danielle Lang, Ms B Pekarsky |
| Scheme | Research Grant |
| Role | Investigator |
| Funding Start | 2000 |
| Funding Finish | 2000 |
| GNo | G0180200 |
| Type Of Funding | Contract - Aust Non Government |
| Category | 3AFC |
| UON | Y |
Research Supervision
Number of supervisions
Past Supervision
| Year | Level of Study | Research Title | Program | Supervisor Type |
|---|---|---|---|---|
| 2021 | PhD | Impact of Diabetes on Women's Health Outcomes: Survival, Healthy Life Expectancy, and Health Related Quality of Life | PhD (Health Economics), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Research Projects
Patient and Surgeon preferences for sham surgery trials 2019 -
Publications
Wall L, Hinwood M, Lang D, Smith A, Bunzli S, Clarke P, et al., 'Attitudes of patients and surgeons towards sham surgery trials: a protocol for a scoping review of attributes to inform a discrete choice experiment', BMJ OPEN, 10 (2020)
Bunzli S, Choong E, Shadbolt C, Wall L, Nelson E, Schilling C, et al., 'Placebo Surgery Controlled Trials: Do They Achieve What They Set Out To Do? A Systematic Review.', Ann Surg, 273 1102-1107 (2021) [C1]
Collaborators
| Name | Organisation |
|---|---|
| Doctor Madeleine Hinwood | University of Newcastle |
| Ms Danielle Leigh Lang | University of Newcastle |
Edit
Ms Danielle Lang
Position
Research Academic
School of Medicine and Public Health
College of Health, Medicine and Wellbeing
Contact Details
| danielle.lang@newcastle.edu.au | |
| Phone | (02) 4014 3002 |
| Fax | (02) 4960 2088 |
Office
| Room | NM2.545 |
|---|---|
| Building | Calvary Mater Newcastle Level 5 - New Med 2 |
| Location | Mater Hospital , |
Connect with me
